| Original language | English (US) |
|---|---|
| Pages (from-to) | 1223-1224 |
| Number of pages | 2 |
| Journal | Journal of the American Society of Nephrology |
| Volume | 33 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2022 |
ASJC Scopus subject areas
- Nephrology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange. / Moura, Marta Casal; Soler, Maria José; Sethi, Sanjeev et al.
In: Journal of the American Society of Nephrology, Vol. 33, No. 6, 06.2022, p. 1223-1224.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange
AU - Moura, Marta Casal
AU - Soler, Maria José
AU - Sethi, Sanjeev
AU - Fervenza, Fernando C.
AU - Specks, Ulrich
N1 - Funding Information: F.C. Fervenza reports consultancy for Alexion Pharmaceuticals, Alnylam, ByoCrystal, Novartis, and Takeda; research funding from Chemocentryx, Genentech, Janssen Pharmaceutical, Questcor/Mallinckrodt, and Retrophin; honoraria from UpToDate; and an advisory or leadership role for UpTo-Date, Kidney International, Nephrology, Nephrology Dialysis and Transplantation, and Journal of the American Society of Nephrology. S. Sethi reports consultancy for Novartis and honorarium for teaching, grand rounds, lectures, UpToDate, and reviewing slides for a study for Novartis. M.J. Soler Romeo reports consultancy for AstraZeneca, Bayer, Boehringer, Esteve, ICU Medical, Jansen, Mundipharma, Novonordisk, and Travere Therapeutics; research funding from Abbvie and Boehringer; honoraria from Astra-Zeneca, Boehringer, Esteve, FMC, ICU Medical, Jansen, Mundipharma, Novonordisk, Otsuka, and Travere; patent U691ES00; an advisory or leadership role for Clinical Kidney Journal, BMC Nephrology, ex ERA-EDTA Council member, SAB ERA-EDTA, and elected editor-in-chief of Clinical Kidney Journal; participating in a speakers’ bureau for AstraZeneca, Bayer, Boehringer, Esteve, FMC, Jansen, Mundipharma, Novonordisk, and Vifor; and other interests or relationships with Sociedad Española de Nefrología and Sociedad Catalana de Nefrologia (member). U. Specks reports consultancy for AstraZeneca and ChemoCentryx; ownership interest with Abbvie, Johnson & Johnson, Pfizer, and Viatris; research funding from AstraZeneca, Boehringer Ingelheim, Bristol Myer Squibb, Genentech, and GSK; and patents or royalties from Mayo Foundation and UpToDate for education and research. All remaining authors have nothing to disclose.
PY - 2022/6
Y1 - 2022/6
UR - http://www.scopus.com/inward/record.url?scp=85131224941&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131224941&partnerID=8YFLogxK
U2 - 10.1681/ASN.2022020164
DO - 10.1681/ASN.2022020164
M3 - Letter
C2 - 35410878
AN - SCOPUS:85131224941
SN - 1046-6673
VL - 33
SP - 1223
EP - 1224
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
IS - 6
ER -